At a glance
ClinicalIndex Comparison RecordN/ACompleted· 78 enrolled
Drug / intervention
Promoting Resilience in Stress Management (PRISM) +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease
In Brief
A clinical study evaluating Promoting Resilience in Stress Management (PRISM) and Usual Care for Congenital Heart Disease. Completed, enrolled 78 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the feasibility and preliminary efficacy of the Promoting Resilience in Stress Management (PRISM) intervention in patients with adult congenital heart disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongenital Heart Disease
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMar 2023
Primary CompletionJul 2024
TodayJul 2026
First PostedFeb 4, 2021
Enrollment StartMar 15, 2023
Primary CompletionJul 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago
Interventions
Promoting Resilience in Stress Management (PRISM)behavioral
Develops personal "resilience resources" through 1:1 sessions with a PRISM coach.
Usual Careother
No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.